[Immunomodulating and antitumor activity of polysaccharides of plant origin].
The effect of the polysaccharides tagetan, palustran, and zymosan injections to BALB/c mice on the formation of cytotoxic T-lymphocytes in allogenic mixed culture has been studied. Lymphocytes from a 5-day-old mixed culture were characterized by the greatest cytotoxic activity, with spleenocytes serving as reacting cells in mice injected 12-50 mg/kg of tagetan, 20 mg/kg of zymosan and 10-100 mg/kg of palustran, 7, 3 and 5 days, respectively, before the beginning of allogeneic stimulation in vitro. To determine correlation between immunostimulating and antitumor activity 25 mg/kg of tagetan every 14 days, 20 mg/kg of zymosan every 6 days, and 10 mg/kg of palustran every 6 days, were injected to BALB/c and BALB/c nu/nu mice prior to and following subcutaneous implantation of Crocker sarcoma cells. By the end of the first month of immunotherapy the tumour size in mice on tagetan or zymosan was 2-2,5 times smaller than in control animals. Tumour growth inhibition with palustran was about 30%. Polysaccharide administration to BALB/c nu/nu mice was not accompanied by tumour growth inhibition. The data obtained suggest that inhibition of Crocker sarcoma growth in mice injected the above polysaccharides is mediated by stimulation of antitumour T-cell activity.
Sergeev
A V
AV
Revazova
E S
ES
Denisova
S I
SI
Kalatskaia
O V
OV
Rytenko
A N
AN
D000276:Adjuvants, Immunologic / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology* / Q000627:therapeutic use; D003601:Cytotoxicity Tests, Immunologic; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D007739:L Cells / Q000187:drug effects; D007959:Lymphocyte Culture Test, Mixed; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008809:Mice, Inbred C3H; D009368:Neoplasm Transplantation; D008517:Phytotherapy; D010946:Plants, Medicinal; D011134:Polysaccharides / Q000494:pharmacology* / Q000627:therapeutic use; D012510:Sarcoma 180 / Q000188:drug therapy; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects; D013997:Time Factors
D000276:Adjuvants, Immunologic; D000972:Antineoplastic Agents, Phytogenic; D011134:Polysaccharides; C047612:palustran; C047613:tagetan
Immunomoduliruiushchaia i protivoopukholevaia aktivnost' polisakharidov rastitel'nogo proiskhozhdeniia.